Mesasal Enteric Coated Alternatives Compared
| Mesasal Enteric Coated (mesalamine) | Humira (adalimumab) | Entyvio (vedolizumab) |
|
|---|
| Mesasal Enteric Coated (mesalamine) | Humira (adalimumab) | Entyvio (vedolizumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Ulcerative Colitis - Maintenance, Ulcerative Colitis - Active, Crohn's Disease - Maintenance, Inflammatory Bowel Disease, Ulcerative Colitis, Ulcerative Proctitis. Mesasal Enteric... View more |
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Related suggestions Ulcerative Colitis
Crohn's Disease, Maintenance
|
|||||||||||||||
| More about (mesalamine) | More about Humira (adalimumab) | More about Entyvio (vedolizumab) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Mesasal Enteric Coated has an average rating of 8.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Humira has an average rating of 6.4 out of 10 from a total of 702 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 30% reported a negative effect. |
Entyvio has an average rating of 6.3 out of 10 from a total of 166 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 28% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Mesasal Enteric Coated side effects |
View all Humira side effects |
View all Entyvio side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
| Lower cost generic approved |
N/A |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Humira prices |
View all Entyvio prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Other mesalamine brands include: Apriso, Asacol, Asacol HD, Canasa, Canasa Pac, Delzicol, Lialda, Pentasa, Rowasa, Rowasa Sulfite Free, Zaldyon View more | Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | Other vedolizumab brands include: Entyvio Pen | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
10 hours |
480 hours |
600 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category B
No proven risk in humans
Excluding Asacol And Asacol HD
Category C
Risk cannot be ruled out
Asacol And Asacol HD See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 121 drugs are known to interact with Mesasal Enteric Coated:
|
A total of 554 drugs are known to interact with Humira:
|
A total of 169 drugs are known to interact with Entyvio:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
December 31, 2002 |
May 20, 2014 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Professional Resources | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Omvoh
Omvoh is used to treat moderate to severe ulcerative colitis or Crohn's disease in adults. This ...
Entyvio
Entyvio (vedolizumab) is used to treat ulcerative colitis (UC) and Crohn's disease, reducing ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Humira
Humira is a tumor necrosis factor blocker used to treat many inflammatory conditions in adults ...
Remicade
Remicade is used to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn's ...
Lialda
Lialda (mesalamine) is used to treat ulcerative colitis, proctitis and proctosigmoiditis. Includes ...
Inflectra
Inflectra (infliximab-dyyb) is a monocloncal antibody used to treat a range of inflammatory ...
Apriso
Apriso (mesalamine) is used to treat ulcerative colitis, proctitis, and proctosigmoiditis. Includes ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.